Patent Application
20200347130
The present disclosure claims the priority of Chinese patent application 201711107331.5, filed on Nov. 10, 2017, the contents of which are incorporated herein by its entirety.
The present disclosure relates to a CD96 antibody and an antigen-binding fragment thereof. Further, the present disclosure also relates to a chimeric antibody and a humanized antibody comprising the CDR region of CD96 antibody. The present disclosure also relates to a pharmaceutical composition comprising the CD96 antibody and the antigen-binding fragment thereof, and the use of same as a diagnostic agent and a therapeutic agent for CD96 related diseases.
The statements herein merely provide background information related to the present invention and do not necessarily constitute prior arts.
In 1992, Wang and colleagues discovered and cloned a new cell membrane-type molecule, which was named TACTILE (T cell activation increased late expression). The molecule was subsequently named CD96 at an international workshop and conference on human leukocyte differentiation antigens. CD96 molecules are expressed on normal T cells, T cell clones and certain transformed T cells. Peripheral blood T cells expressed low levels of CD96 molecules, which was significantly upregulated after activation, and reached an expression peak on day 6-9 after stimulation. Following stimulation of an alloantigen, expression of CD96 on Natural Killer (NK) cells was also upregulated. CD96 belongs to the immunoglobulin superfamily, and its extracellular membrane region contains three immunoglobulin-like domains, with a total of 15 N-linked glycosylation sites and a stem-like domain having highly O-linked glycosylation rich in serine/threonine/proline residues. CD96 has a transmembrane region containing 24 amino acid residues, a cytoplasmic region containing 44 amino acid residues, and a region rich in basic animo acid/proline. In the more than ten years since the CD96 molecule was cloned, there has been no significant progress in the study of the molecule because it is unclear what its ligand is. CD96 is widely expressed in hematopoietic and non-hematopoietic cell lines. CD96 is also expressed in normal human CD4+T cells, CD8+T cells, monocytes and NK cells. After Phytohaemaggiutinin (PHA) stimulation, CD96 expression in CD4+T cells, CD8+T cells and NK cells was significantly upregulated, confirming that CD96 exhibits increased activation expression. However, PHA did not significantly upregulate the expression of CD96 in monocytes, suggesting that different cells demonstrate different characteristics in regulating the expression of CD96 molecules. Until 2004, Fuchs and colleagues discovered that NK cells can recognize PVR (CD155) through CD96, promote the adhesion of NK cells to target cells which express CD155, promote the cytotoxicity of NK cells and mediate the internalization of CD155 on the surface of target cells. Since PVR (CD155) is highly expressed in certain tumor cells, this receptor system can play an important role in the recognition and killing of tumors by NK cells. However, the current understanding of the expression and function of CD96 is limited. It is believed that with the continuous understanding of the function of this molecule, CD96 should attract more attention.
The cytoplasmic region of the CD96 molecule contains an immunoreceptor tyrosine inhibitory motif (ITIM), which is highly conserved among different species. It is generally believed that ITIM inhibits signal transmission. Recent studies found that certain molecules can transmit activation signals through ITIM. Receptors containing ITIM motifs play a key role in the activation of signal transmission and the recruitment of SHP-2. Therefore, CD96 can mediate inhibition of NK cell activity. Additionally, CD96 and CD226 exhibit homologous sequences. According to current studies, it is believed that those two molecules inhibit or activate NK cells through binding to CD155, respectively, so as to regulate NK cell function.
Currently, only CD96 antibody molecules reported in CN105636983 and CN105636985, etc. show reduced immunosuppression in animals, or CD96 antibody molecules in EP2097535 are used to eliminate CD96+ AMLSC cells. Specific CD96 antibody molecules have not been reported, and CD96 antibody molecules have not been clinically studied. Therefore, it is necessary to develop CD96 antibodies with high affinity and targeting specific epitopes for studying the functions of CD96 and CD96 antibody drugs.
The present disclosure provides a monoclonal antibody or an antigen-binding fragment (also referred to as CD96-binding molecules) that specifically binds the amino acid sequence or three-dimensional structure of CD96.
In one aspect, the present disclosure provides a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human CD96, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein:
(i) the heavy chain variable region comprises HCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the HCDR1, HCDR2 and HCDR3, respectively, wherein the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO: 16, 17 and 18, respectively; the light chain variable region comprises LCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the LCDR1, LCDR2 and LCDR3, respectively, wherein the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO: 19, 20 and 21, respectively; or
(ii) the heavy chain variable region comprises HCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the HCDR1, HCDR2 and HCDR3, respectively, wherein the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO: 22, 23 and 24, respectively; the light chain variable region comprises LCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the LCDR1, LCDR2 and LCDR3, respectively, wherein the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO: 25, 26 and 27, respectively; or
(iii) the heavy chain variable region comprises HCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the HCDR1, HCDR2 and HCDR3, respectively, wherein the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO: 28, 29 and 30, respectively; the light chain variable region comprises LCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the LCDR1, LCDR2 and LCDR3, respectively, wherein the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO: 31, 32 and 33, respectively; or
(iv) the heavy chain variable region comprises HCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations of the HCDR1, HCDR2 and HCDR3, respectively, wherein the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO: 34, 35 and 36, respectively; the light chain variable region comprises LCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations of the LCDR1, LCDR2 and LCDR3, respectively, wherein the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO: 37, 38 and 39, respectively; or
(v) the heavy chain variable region comprises HCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the HCDR1, HCDR2 and HCDR3, respectively, wherein the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO: 40, 41 and 42, respectively; the light chain variable region comprises LCDR variants selected from the group consisting of 3, 2, 1 or 0 amino acid mutations on the basis of the LCDR1, LCDR2 and LCDR3, respectively, wherein the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO: 43, 44 and 45, respectively. The amino acid mutation is preferably an amino acid substitution, and more preferably, a conservative amino acid substitution.
In some embodiments, CDR variants of the monoclonal antibody or the antigen-binding fragment (including 3 heavy chain CDRs and 3 light chain CDRs) having 3, 2 or 1 amino acid mutations are the CDR variants having 3, 2 or 1 amino acid mutations, which are screened by affinity maturation methods.
In some embodiments, the monoclonal antibody or the antigen-binding fragment has an affinity (KD) to CD96 of less than 10−7M, less than 10−8M, less than 10−9M, less than 10−19M or less than 10−11M.
In some embodiments, the present disclosure provides a monoclonal antibody or an antigen-binding fragment thereof that specifically binds human CD96, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein:
(vi) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 regions having the amino acid sequences of SEQ ID NO: 16, 17 and 18, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 regions having the amino acid sequences of SEQ ID NO: 52, 20 and 21, respectively, wherein the LCDR1 is preferably selected from any one of SEQ ID NO: 19, 108, 109 and 110; or
(vii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 regions having the amino acid sequences of SEQ ID NO: 22, 23 and 64, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 regions having the amino acid sequences of SEQ ID NO: 25, 26 and 27, respectively, wherein the HCDR3 is preferably selected from any one of SEQ ID NO: 24, 111, 112, 113, 114, 115 and 116; or
(viii) the heavy chain variable region comprises CDR1, HCDR2 and HCDR3 regions having the amino acid sequences of SEQ ID NO: 28, 29 and 30, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 regions having the amino acid sequences of SEQ ID NO: 31, 32 and 33, respectively; or
(ix) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 regions having the amino acid sequences of SEQ ID NO: 34, 35 and 36, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 regions having the amino acid sequences of SEQ ID NO: 37, 38 and 39, respectively; or
(x) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 regions having the amino acid sequences of SEQ ID NO: 40, 119 and 42, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 regions shown as the amino acid sequences of SEQ ID NO: 43, 44 and 45, respectively, wherein the HCDR2 is preferably selected from SEQ ID NO: 41, 120 or 121.
In some embodiments, the monoclonal antibody or the antigen-binding fragment is a recombinant antibody, preferably selected from a murine antibody, a chimeric antibody and a humanized antibody.
In some embodiments, the monoclonal antibody or the antigen-binding fragment thereof comprises a light chain variable region, or a heavy chain variable region, or a light chain variable region and a heavy chain variable region selected from the following:
(a) the heavy chain variable region having the sequence of any one of SEQ ID NO: 6, 46, 49, 50 and 51, or a variant thereof, and/or the light chain variable region having the sequence of any one of SEQ ID NO: 7, 47, 48, 53, 54, 55, 56, 57 and 58, or a variant thereof; or
(b) the heavy chain variable region having the sequence of any one of SEQ ID NO: 8, 59, 62, 63, 65, 66, 67, 68, 69 and 70, or a variant thereof, and/or the light chain variable region having the sequence of any one of SEQ ID NO: 9, 60 and 61, or a variant thereof; or
(c) the sequence of the heavy chain variable region having the sequence of any one of SEQ ID NO: 10, or a variant thereof, and/or the light chain variable region having the sequence of any one of SEQ ID NO: 11, or a variant thereof;
(d) the heavy chain variable region having the sequence of any one of SEQ ID NO: 12, 71, 75, 76 and 77, or a variant thereof, and/or the light chain variable region having the sequence of any one of SEQ ID NO: 13, 72, 73 and 74, or a variant thereof; or
(e) the heavy chain variable region having the sequence of any one of SEQ ID NO: 14, 78, 82, 83, 84, 122 and 123, or a variant thereof, and/or the light chain variable region having the sequence of any one of SEQ ID NO: 15, 79, 80, and 81, or a variant thereof;
Wherein the variant in (a) to (e) has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations in the sequence of the framework region of the light chain variable region or the heavy chain variable region.
In some embodiments, the monoclonal antibody or the antigen-binding fragment thereof comprises a heavy chain variable region selected from the group consisting of:
(a) a heavy chain variable region or a variant thereof having the amino acid sequence of shown in any one of SEQ ID NO: 6, 46, 49, 50 and 51;
(b) a heavy chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 8, 59, 62, 63, 65, 66, 67, 68, 69 and 70;
(c) a heavy chain variable region or a variant thereof having the amino acid sequence of SEQ ID NO: 10;
(d) a heavy chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 12, 71, 75, 76 and 77;
(e) a heavy chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 14, 78, 82, 83, 84, 122 and 123;
Wherein the variant in (a) to (e) has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations in the framework region sequence of the light chain variable region or the heavy chain variable region.
In some embodiments, the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable region selected from the group consisting of:
(a) a light chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 7, 47, 48, 53, 54, 55, 56, 57 and 58;
(b) a light chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 9, 60 and 61;
(c) a light chain variable region or a variant thereof having the amino acid sequence of SEQ ID NO: 11;
(d) a light chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 13, 72, 73 and 74;
(e) a light chain variable region or a variant thereof having the amino acid sequence of any one of SEQ ID NO: 15, 79, 80 and 81;
Wherein the variant in (a) to (e) has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations in the framework region sequence of the light chain variable region or the heavy chain variable region, the amino acid mutation is preferably a back mutation of a framework region amino acid.
In some embodiments, the antibody or antigen-binding fragment comprises:
(f) the heavy chain variable region having the sequence selected from any one of SEQ ID NOs: 6, 46, 49, 50 and 51, and the light chain variable region having the sequence selected from any one of SEQ ID NO: 7, 47, 48, 53, 54, 55, 56, 57 and 58; or
(g) the heavy chain variable region having the sequence selected from the sequences shown in any one of SEQ ID NOs: 8, 59, 62, 63, 65, 66, 67, 68, 69 and 70, and the light chain variable region having the sequence selected from any one of SEQ ID NO: 9, 60, and 61; or
(h) the heavy chain variable region having the sequence of SEQ ID NO: 10, and the light chain variable region having the sequence of SEQ ID NO: 11;
(i) the heavy chain variable region having the sequence selected from any one of SEQ ID NOs: 12, 71, 75, 76 and 77, and the light chain variable region having the sequence selected from any one of SEQ ID NOs: 13, 72, 73 and 74; or
(j) the heavy chain variable region having the sequence selected from any one of 14, 78, 82, 83, 84, 122 and 123, and the light chain variable region having the sequence selected from any one of SEQ ID NOs: 15, 79, 80 and 81.
In some embodiments, the antibody is a full-length antibody, further comprising a human antibody constant region, preferably a human antibody heavy chain constant region of SEQ ID NO: 117 and/or a human antibody light chain constant region of SEQ ID NO: 118.
In some embodiments, the antigen-binding fragment is selected from the group consisting of Fab, Fab′, F(ab′)2, single chain variable fragment (scFv), dimerized domain V (diabody), disulfide stabilized Fv (dsFv) and antigen-binding fragments of CDR-containing peptides.
In some embodiments, the antibody or antigen-binding fragment binds to human CD96 with an affinity of a KD value of 1×10−7M to 1×10−12M as determined by, for example, surface plasmon resonance (BIACORE).
In another aspect, the present disclosure also provides an isolated monoclonal antibody or an antigen-binding fragment thereof that competes with said monoclonal antibodies (i)-(x) or a-j or an antigen-binding fragment thereof to bind to human CD96.
In some embodiments, the monoclonal antibody or the antigen-binding fragment thereof has at least one of the following characteristics:
(i) binding to human CD96 with an affinity of a KD value of 1×10−7M to 1×10−12M as determined by, for example, surface plasmon resonance (BIACORE);
(ii) cross-reacting with CD96 of cynomolgus monkey or rhesus monkey;
(iii) blocking the binding of human CD96 to human CD155;
(iv) increased activation of NK cells and/or T cells;
(v) blocking the inhibition of NK cell activation induced by the binding of CD96 to CD155.
In some embodiments, the monoclonal antibody or the antigen-binding fragment thereof binds to a region in the extracellular region of human CD96 (SEQ ID NO: 3) as shown by IAVYHPQYGFYCAYGRPCES.
In another aspect, the present disclosure also provides a multispecific antibody comprising a light chain variable region and/or a heavy chain variable region of anti-CD96 antibody or the antigen-binding fragment thereof described above.
In another aspect, the present disclosure also provides a single chain antibody comprising a light chain variable region and/or a heavy chain variable region of the anti-CD96 antibody or the antigen-binding fragment thereof described above.
In another aspect, the present disclosure also provides a pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody or the single chain antibody described above, and one or more pharmaceutically acceptable carriers, diluents, buffers, or excipients Preferably, the pharmaceutical composition can contain 0.01 to 99% by weight of the anti-CD96 antibody or the antigen-binding fragment thereof in a unit dose, or the amount of the monoclonal antibody or the antigen-binding fragment thereof in a unit dose of the pharmaceutical composition is 0.1-2000 mg, preferably 1-1000 mg.
In another aspect, the present disclosure also provides an isolated nucleic acid molecule encoding the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody, or the single chain antibody as defined in any one of the preceding aspects.
In another aspect, the present disclosure also provides a recombinant vector comprising said isolated nucleic acid molecule.
In another aspect, the present disclosure also provides a host cell transformed with said recombinant vector, wherein the host cell is selected from a prokaryotic cell and a eukaryotic cell, preferably a eukaryotic cell, more preferably a mammalian cell.
In another aspect, the present disclosure also provides a method for producing the monoclonal antibody or the antigen-binding fragment thereof as defined in any one of the preceding aspects, wherein the method comprises culturing said host cell in a medium to produce and accumulate the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody or the single chain antibody as defined in any one of the preceding aspects, and harvesting the monoclonal antibody or the antigen-binding fragment thereof from a culture.
In another aspect, the present disclosure also provides a method for detecting or measuring human CD96 in vitro comprising using the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody, or the single chain antibody as defined in any one of the preceding aspects.
In another aspect, the present disclosure also provides a use of the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody, or the single chain antibody as defined in any one of the preceding aspects in the preparation of a reagent for detecting or measuring human CD96.
In another aspect, the present disclosure also provides a method of reducing or alleviating immunosuppression comprising administering to a subject a therapeutically effective amount of the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody, or the single chain antibody, or the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects.
In another aspect, the present disclosure also provides a method for enhancing the activity of NK cells comprising a step of reducing CD96 activity using the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody or the single chain antibody, or the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects.
In another aspect, the present disclosure also provides a use of the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody, or the single chain antibody, or the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects in the preparation of a medicament for enhancing the activity of NK cells.
In another aspect, the present disclosure also provides a method for treating diseases associated with human CD96 comprising administering to a subject a therapeutically effective amount of the monoclonal antibody or the antigen-binding fragment thereof, or the multispecific antibody, or the single chain antibody, or the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects, to treat diseases associated with human CD96, wherein the disease is preferably a tumor, a cancer or an infectious disease.
In another aspect, the present disclosure also provides a use of the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody, the single chain antibody, the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects, or a combination thereof, in the preparation of a medicament for treating or preventing a disease or disorder, wherein the disease or disorder is a disease associated with human CD96, the disease or disorder is preferably a tumor, a cancer or an infectious disease.
In another aspect, the present disclosure also provides a medicament of the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody, the single chain antibody, the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects.
In another aspect, the present disclosure also provides the monoclonal antibody or the antigen-binding fragment thereof, the multispecific antibody, the single chain antibody, or the pharmaceutical composition or the isolated nucleic acid molecule as defined in any one of the preceding aspects as a medicament, wherein the medicament is used for the treatment of diseases associated with human CD96, wherein the disease is preferably a tumor, a cancer or an infectious disease.
Alternatively, the cancer can be any cancer that responds to at least partially blocked CD96-mediated immunosuppression, suppression, or peripheral tolerance. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancy. More specific examples of cancer include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell/histocyte-rich large B-cell lymphoma, multiple myeloma, myeloid cell leukelia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, gastric carcinoma, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, gastric carcinoma, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, hepatobiliary cancer, central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative tumor, neuroendocrine neoplasm, Merkel cell carcinoma, testicular cancer, and skin cancer. In some embodiments, the cancer is metastatic and able to migrate to another site, tissue or organ within the body and form a tumor at that site.
Typically, a disease or condition that responds to at least partially blocked CD96-mediated immunosuppression, suppression, or peripheral tolerance is any disease or condition that enhances or restores immune surveillance to benefit a subject suffering from the disease or condition. The diseases and conditions may include persistent diseases or conditions that can be controlled or suppressed by cell-mediated immunity. Non-limiting examples include tumors, cancer or infectious diseases. Specifically, examples of cancers related to the present disclosure include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancy. More specific examples of the cancers include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell/histocyte-rich large B-cell lymphoma, multiple myeloma, myeloid cell leukelia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, gastric carcinoma, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, gastric carcinoma, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, hepatobiliary cancer, central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative tumor, neuroendocrine neoplasm, Merkel cell carcinoma, testicular cancer, and skin cancer. In some embodiments, the cancer is metastatic cancer that has the ability to migrate to another site, tissue or organ within the body and form a tumor at that site.
The infectious diseases involved include all diseases caused by a virus or pathogen infection which can be infected through respiratory organs, blood contact or skin contact. Non-limiting examples of these infectious diseases include, but are not limited to, hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza, and Epstein-Barr virus (EBV) infection, Herpes simplex virus (HSV includes HSV1 and HSV2) infection, varicella-zoster virus (VSV) infections, cytomegalovirus (CMV) infections, and the like.
The CD96 monoclonal antibody or the antigen-binding fragment of the present disclosure has high specificity and high affinity to CD96. The immunogenicity of the humanized antibody is greatly reduced, while the specificity, high affinity and activity of the murine antibody are completely retained.
In order to facilitate understanding the present invention, certain technical and scientific terms are specifically defined below. Unless otherwise defined herein, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which this invention belongs.
Three-letter codes and one-letter codes of amino acids used in the present disclosure are described in J. biol. chem, 243, p 3558 (1968).
The ‘antibody’ in the present disclosure refers to an immunoglobulin, which is a tetrapeptide chain structure formed by connecting two identical heavy chains and two identical light chains through interchain disulfide bonds. The amino acid composition and sequence of the constant region of the immunoglobulin heavy chain are different, so is their antigenicity. According to this, immunoglobulins can be divided into five classes, or called isotypes, that is, IgM, IgD, IgG, IgA and IgE, and the corresponding heavy chains are μ chain, δ chain, γ chain, α chain, and ε chain, respectively. Ig of the same class can be divided into different subclasses according to the difference in amino acid composition of hinge regions and the number and position of heavy chain disulfide bonds, for example, IgG can be classified into IgG1, IgG2, IgG3 and IgG4. The light chain is divided into a κ chain or a λ chain by the difference of constant regions. Each of the five classes of Ig can have a κ chain or λ chain.
In the present disclosure, the antibody light chain as defined in the present disclosure may further comprise a light chain constant region, and the light chain constant region comprises a human or murine κ, λ chain, or a variant thereof.
In the present disclosure, the antibody heavy chain as defined in the present disclosure may further comprise a heavy chain constant region, and the heavy chain constant region comprises a human or murine IgG1, IgG2, IgG3, IgG4 or a variant thereof.
The variable region (Fv region) comprises about 110 amino acids with great sequence variation, which are located at the N-terminus of the heavy chain and the light chain of the antibody; the constant region comprising the remaining amino acids is relatively stable in sequence and located at the C-terminus of that of antibody. The variable region comprises three hypervariable regions (HVRs) and four relatively conserved framework regions (FRs). Three hypervariable regions determine the specificity of the antibody, which are also known as complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of 3 CDR regions and 4 FR regions. The order from amino terminal to carboxy terminal is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Three CDR regions of the light chain are referred to as LCDR1, LCDR2 and LCDR3; and three CDR regions of the heavy chain are referred to as HCDR1, HCDR2 and HCDR3. The number and location of CDR amino acid residues in the LCVR regions and HCVR regions of the antibody or antigen-binding fragment as define in the present disclosure conform to the known Kabat numbering system (LCDR1-3, HCDR1-3).
The antibodies of the present disclosure include murine antibodies, chimeric antibodies, humanized antibodies, preferably humanized antibodies.
The term ‘murine antibody’ in this disclosure is an anti-human CD96 monoclonal antibody prepared according to the knowledge and skill in the art. Test subjects are injected with CD96 antigen during preparation, and hybridomas expressing antibodies with the desired sequence or functional characteristics are isolated. In a preferred embodiment of the present disclosure, the anti-murine CD96 antibody or the antigen-binding fragment thereof may further comprise a light chain constant region comprising a murine κ, λ chain or variants thereof, or further comprise a heavy chain constant region of murine IgG1, IgG2, IgG3 or variants thereof.
The term ‘chimeric antibody’ is an antibody obtained by fusing the variable region of a murine antibody with the constant region of a human antibody, which can reduce the immune response induced by the murine antibody. To construct a chimeric antibody, the first step is to establish a hybridoma that secrets murine specific monoclonal antibody, then clone the variable region gene from the murine hybridoma cell, and then clone the constant region gene of the human antibody as required. The murine variable region gene is linked with the human constant region gene to form a chimeric gene and subsequently, the chimeric gene is inserted into an expression vector Finally, the chimeric antibody molecule is expressed in a eukaryotic system or a prokaryotic system. In a certain embodiment of the present disclosure, the antibody light chain of the CD96 chimeric antibody further comprises a light chain constant region comprising a human κ, λ chain or a variant thereof. The antibody heavy chain of the CD96 chimeric antibody further comprises a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4 or a variant thereof, preferably a human IgG1, IgG2 or IgG4 heavy chain constant region, or a virant of IgG1, IgG2 or IgG4 heavy chain constant region with amino acid mutation (e.g., YTE mutation or back mutation).
The term ‘humanized antibody’ refers to an antibody produced by grafting a murine CDR sequence into a framework of human antibody variable region, that is, an antibody produced from different type of human germline antibody framework sequences. It can overcome the heterogeneous response induced by the chimeric antibody, which carries a large amount of murine protein components. These framework sequences can be obtained from a public DNA database containing germline antibody gene sequences or published references. For example, germline DNA sequences of human heavy and light chain variable region genes can be obtained from the ‘VBase’ human germline sequence database (Woldwide Website: mrccpe.com.ac.uk/vbase), and in Kabat, E A, etc., 1991 Sequences of Proteins of Immunological Interest, 5th edition. In order to avoid decreased activity caused by decreased immunogenicity, the framework sequence of human antibody variable region can be subjected to minimal reverse mutation or back mutation to maintain the activity. The humanized antibodies of the present disclosure also include humanized antibodies with affinity maturation of CDRs by phage display. In a preferred embodiment of the present disclosure, the murine CDR sequence of the CD96 humanized antibody is selected from the group consisting of SEQ ID NO: 16-21, 22-27, 28-33, 34-39 or 40-45; the human antibody variable region framework is designed and selected, wherein the heavy chain FR sequence on the antibody heavy chain variable region is derived from the human germline heavy chain sequence and the human germline light chain sequence. In order to avoid the decrease in activity caused by the decrease in immunogenicity, the human antibody variable region can be subjected to minimum of reverse mutation (back mutation, that is, amino acid residues in FR from the human antibody is mutated to the amino acid residues in corresponding position of original antibody) to retain activation.
The grafting of CDRs may result in a decrease in the affinity of the produced CD96 antibody or the antigen-binding fragment thereof to the antigen due to changes in the framework residues in contact with the antigen. These interactions can be the result of highly mutated somatic cells. Therefore, it may still be necessary to graft donor framework amino acids to the framework of a humanized antibody Amino acid residues involved in antigen binding from non-human CD96 antibody or the antigen-binding fragment thereof can be identified by examining the sequence and structure of the variable region of murine monoclonal antibody. Residues in the CDR donor framework that differ from the germline can be considered related. If the closest germline cannot be determined, the sequence can be compared to the consensus sequence of subtype or the consensus sequence of murine sequence with a high percentage of similarity. Rare framework residues are believed to be the result of high frequency mutations of somatic cells and thus, play an important role in binding.
In the description similar to ‘CDR variants with 3, 2, 1 or 0 amino acid mutations of the CDR1, CDR2 and CDR3 having SEQ ID NO: X, SEQ ID NO: Y and SEQ ID NO: Z, respectively’, an exemplary explanation is the mutations of CDR may comprise 3, 2, 1 or 0 amino acid mutations, and the same or different number of amino acid residues may be optionally selected between CDR1, CDR2 and CDR3 for mutation. For example, on the basis of the CDR1, CDR2 and CDR3 shown in SEQ ID NO: X, SEQ ID NO: Y and SEQ ID NO: Z, 1 amino acid of mutation is made to CDR1 and 0 amino acid of mutation is made to CDR2 and CDR3. When 0 amino acid of mutation is made to a CDR, the CDR variant with 0 amino acid mutation is still the CDR itself.
The term ‘antigen-binding fragment’ or ‘functional fragment’ of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind an antigen (eg, CD96). It has been shown that fragments of a full-length antibody can be used to achieve the antigen-binding function of the antibody. Examples of binding fragments indicated in the term ‘antigen-binding fragment’ of an antibody include (i) a monovalent Fab fragment consisting of VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment including bivalent fragment of two Fab fragments connected by a disulfide bridge on the hinge region, (iii) Fd fragment consisting of VH and CH1 domains; (iv) Fv fragment consisting of VH domain and VL domain of single-armed of the antibody; (v) a single domain or dAb fragment (Ward et al. (1989) Nature 341: 544-546) consisting of a VH domain; and (vi) an isolated complementary determining region (CDR) or (vii) optionally a combination of two or more separate CDRs connected by a synthetic linker. Additionally, although separate genes encode the two domains VL and VH of the Fv fragment, these genes can be combined through a synthetic linker using recombinant methods. Consequently, this produces a single protein chain that is a monovalent molecule formed by pairing VL and VH regions (referred to as single-chain Fv (scFv); see refs, eg, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). These scFvs are also intended to be included in the term “antigen-binding fragment” of an antibody. The antibody fragments are obtained using conventional techniques known to those skilled in the art, and screened by their functionality in the same manner as intact antibodies. Antigen-binding moieties can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact immunoglobulins. The antibodies may be antibodies of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtypes), IgA1, IgA2, IgD, IgE or IgM antibodies.
The antigen-binding fragments of the present disclosure include Fab, F(ab′)2, Fab′, single chain variable fragment (scFv), dimerized domain V (diabody), disulfide stabilized Fv (dsFv), CDR-containing peptides, etc.
Fab is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity of the fragments obtained by treating IgG antibody molecule with a papain (cleaves the amino acid residue at position 224 of the H chain), wherein about half of the N-terminal side of the H chain and the entire L chain are connected together by disulfide bonds.
The Fab of the present disclosure can be produced by treating the monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of human CD96 or its three-dimensional structure with papain. Additionally, the Fab can be produced by inserting DNA encoding the Fab of the antibody into a prokaryotic expression vector or a eukaryotic expression vector and transforming the vector into a prokaryote or eukaryote to express the Fab.
F(ab′)2 is an antibody fragment having a molecular weight of about 100,000, antigen-binding activity and two Fab regions connected at hinge positions obtained by cleaving the lower portions of two disulfide bonds in IgG hinge region with enzyme pepsin.
F(ab′)2 of the present disclosure can be produced by treating the monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of human CD96 or its three-dimensional structure with pepsin. In addition, the F(ab′)2 can be produced by connecting Fab's described below with a thioether bond or a disulfide bond.
Fab′ is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity obtained by cleaving the disulfide bond of the hinge region of F(ab′)2 described above. The Fab′ of the present disclosure can be produced by treating F(ab′)2 of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of CD96 or its three-dimensional structure with a reducing agent such as dithiothreitol.
In addition, the Fab′ can be produced by inserting DNA encoding a Fab′ fragment of the antibody into a prokaryotic expression vector or a eukaryotic expression vector and transforming the vector into a prokaryote or eukaryote to express the Fab′.
The term ‘single-chain antibody’, ‘single-chain Fv’ or ‘scFv’ refers to the molecule including an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) conjugated by a linker. These scFv molecules may have a general structure: NH2—VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable linkers of prior arts consist of repeated GGGGS amino acid sequences or variants thereof, for example, using 1-4 repeated variants (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers can be used for the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immuno 1.31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol).
The following steps can be used to produce the scFV of the present disclosure: obtaining the cDNA encoding VH and VL of monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of human CD96 or its three-dimensional structure, constructing the DNA encoding scFv, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then transforming the expression vector into a prokaryote or eukaryote to express the scFv.
Diabodies are antibody fragments in which scFv is dimerized and possess bivalent antigen-binding activity. In a bivalent antigen-binding activity, the two antigens may be the same or different.
The following steps can be used to produce the diabody of the present disclosure: obtaining the cDNA encoding VH and VL of the monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region human of CD96 or its three-dimensional structure, constructing the DNA encoding scFv so that the length of the amino acid sequence of the peptide linker is 8 residues or less, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then transforming the expression vector into a prokaryote or eukaryote to express the diabody.
dsFv is obtained by linking a polypeptide in which one amino acid residue in each of VH and VL is substituted by a cysteine residue via disulfide bond between the cysteine residues. The amino acid residues substituted by cysteine residues can be selected according to a known method (Protein Engineering, 7,697(1994)) based on the three-dimensional structure prediction of the antibody.
The following steps can be used to produce the dsFV of the present disclosure: obtaining the cDNA encoding VH and VL of the monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of human CD96 or its three-dimensional structure, constructing DNA encoding dsFv, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then transforming the expression vector into a prokaryote or eukaryote to express the dsFv.
A CDR-containing peptide consists of one or more CDRs that contain VH or VL. Peptides containing multiple CDRs can be conjugated directly or via a suitable peptide linker.
The following steps can be used to produce the CDR-containing peptides of the present disclosure: constructing DNA encoding CDRs containing VH and VL of the monoclonal antibody of the present disclosure that specifically recognizes and binds to the amino acid sequence of the extracellular region of human CD96 or its three-dimensional structure, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then transforming the expression vector into a prokaryote or eukaryote to express the peptide. The CDR-containing peptide can also be produced by a chemical synthesis method such as the Fmoc method or the tBoc method.
The term ‘antibody framework’ as used herein refers to a part of variable domain VL or VH, which serves as a scaffold for the antigen-binding loop (CDR) of the variable domain. In essence, it is a variable domain without CDR.
The term ‘amino acid mutation’ refers to mutation of certain or some animo acid positions on a fragment of polypeptide and variants thereof, wherein the variant can be obtained by substituting, inserting or deleting amino acids at one or some sites on the polypeptide.
The term ‘epitope’ or ‘antigenic determinant’ refers to a part on an antigen to which an immunoglobulin or antibody specifically binds (e.g., certain parts on CD96 molecule). An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-consecutive amino acids in a unique spatial conformation. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, vol. 66, G. E. Morris, Ed. (1996).
The terms ‘specifically bind’, ‘selectively bind’, ‘bind selectively’ and ‘bind specifically’ refer to the binding of an antibody to epitopes on a predetermined antigen. Generally, antibodies bind antigens with an affinity (KD) of less than about 10−8M, such as about less than 10−9M, 10−19M, 10−11M, or less.
The term ‘KD’ refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. Generally, antibodies of the present disclosure bind CD96 with a dissociation equilibrium constant (KD) of less than about 10−7M, such as less than about 10−8M, 10−9M, or 10−19M or less, for example, using surface plasmon resonance (SPR) technology to measure the constant by a BIACORE instrument.
When the term ‘competition’ is used in the case of antigen-binding proteins competing for the same epitope (such as neutralizing antigen-binding proteins or neutralizing antibodies or specifically binding antibodies), it means competition between the antigen-binding proteins. Competition is determined by the following assay: the antigen-binding protein (e.g., an antibody or an immunologically functional fragment thereof) to be tested prevents or inhibits (e.g., reduces) the binding of a reference antigen-binding protein (e.g., a ligand or reference antibody) to a common antigen (e.g., a CD96 antigen or a fragment thereof). Numerous types of competitive binding assays can be used to determine whether one antigen-binding protein competes with another, such as: solid-phase direct or indirect radioimmunoassay (RIA), solid-phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see, eg, Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, eg, Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid phase direct labeling assay, solid phase direct labeling sandwich assay (see, eg, Harlow and Lane, 1988, (Antibodies, A Laboratory Manual), Cold Spring Harbor Press); solid phase direct labeling RIA using 1-125 (see, for example, Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, for example, Cheung, et al., 1990, Virology 176:546-552); and direct labeling RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82); or by a method such as Emobodiment 7 of the present disclosure. Generally, the assays involve the use of a purified antigen (the antigen is on a solid surface or a cell surface) capable of binding to an unlabeled detecting antigen-binding protein and a labeled reference antigen-binding protein. Competitive inhibition is measured by quantifying the amount of label binding to a solid surface or cell in the presence of the test antigen-binding protein. Alternatively, as provided in Embodiment 7 herein of the method for determining competitive binding, competitive inhibition is determined by immobilizing antigen-binding protein A and detecting the change of the labeled antigen signal which pre-binds to the antigen-binding protein. Usually, the competitive inhibition test is confirmed by swapping the positions of antigen-binding protein A and antigen-binding protein B. Antigen-binding proteins identified by the competitive assays (competing antigen-binding protein) include: an antigen-binding protein that binds to the same epitope as a reference antigen-binding protein; and an antigen-binding protein that binds to an epitope adjacent to an epitope that is sufficiently close to the reference antigen-binding protein, while the two epitopes spatially hinder the binding of each other. Generally, when there is an excess of competing antigen-binding proteins, part of the competitive antigen-binding proteins inhibit (e.g., reduce) at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% of the specific binding of the reference antigen-binding protein to the common antigen. In the case of complete competition, the binding of the reference antigen-binding protein to the antigen is inhibited by at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or more. Inhibition of less than 30% is considered non-competitive. In the method for testing competitive binding provided in Embodiment 7, it is considered as competition or partial competition, when the competitive antigen-binding protein inhibits the binding of the reference antigen-binding protein in the degree defined above whether it is as antigen-binding protein A or as antigen-binding protein B.
‘Conservative amino acid modification’ or ‘conservative amino acid substitution’ or ‘conservative amino acid replacement’ refers to amino acids in proteins that are substituted by other amino acids that share similar characteristics (such as charge, side chain size, hydrophobicity/hydrophilicity, main chain conformation and rigidity, etc.), thus, the changes can be made frequently without altering the biological activity or other desired properties (such as antigen affinity and/or specificity) of the proteins. Those skilled in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity of the polypeptide (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., P224 (4th edition)). Moreover, the substitution of structurally or functionally similar amino acid is unlikely to disrupt its biological activity. Exemplary conservative substitutions are set forth in the following table ‘Exemplary conservative amino acid substitutions’.
The term ‘nucleic acid molecule’, as used herein, refers to both DNA molecules and RNA molecules. The nucleic acid molecule may be single-stranded or double-stranded, preferably double-stranded DNA. A nucleic acid is ‘effectively linked’ when it is placed in a functional relationship with another nucleic acid sequence. For example, if a promoter or enhancer affects transcription of a coding sequence, the promoter or enhancer is operatively linked to the coding sequence.
The term ‘vector’ refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. In one embodiment, the vector is a ‘plasmid’, which refers to a circular double-stranded DNA loop to which other DNA segments can be linked. In another embodiment, the vector is a viral vector, wherein other DNA segments can be linked into the viral genome. The vectors disclosed herein are capable of autonomous replication in host cells into which they have been introduced (e.g., bacterial vectors with bacterial origins of replication and episomal mammalian vectors) or can be integrated into the host cell's genome after transfecting into the host cell, thereby replicating together with the host genome (e.g., non-episomal mammalian vectors).
Methods for producing and purifying antibodies and antigen-binding fragments are well known in the prior art, such as Cold Spring Harbor's Antibody Experiment Technical Guide, Chapters 5-8 and 15. For example, mice can be immunized with human CD96 or fragments thereof, and the resulting antibodies can be renatured, purified. The amino acid sequence can be determined using conventional methods. Antigen-binding fragments can also be prepared by conventional methods. The antibody or the antigen-binding fragment as defined in the invention is genetically engineered to add one or more human FR regions into a non-human CDR region. The human FR germline sequence can be obtained by aligning the IMGT human antibody variable region germline gene database and MOE software from ImMunoGeneTics (IMGT) website: imgt.cines.fr, or from the Journal of Immunoglobulins, 200115BN012441351.
The term ‘host cell’ refers to a cell into which an expression vector has been introduced. Host cells maybe microorganism (e.g., bacteria), plant or animal cells. Bacteria that are easy to transform include members of the Enterobacteriaceae family, such as strains of Escherichia coli or Salmonella; Bacilillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese Hamster Ovary Cell Line), HEK293, and NSO cells.
The engineered antibodies or the antigen-binding fragments of the present disclosure can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into a GS expression vector. The recombinant immunoglobulin expression vector can be stably transfected into CHO cells. According to a common recommendation in the prior art, mammalian expression systems can cause glycosylation of antibodies, especially the highly conserved N-terminal site in the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to human CD96. Positive clones can be expanded in serum-free medium in the bioreactor to produce antibodies. The culture medium in which the antibody is secreted can be purified by conventional techniques, for example, an A or G Sepharose FF column with adjusted buffer. Non-specifically bound components are washed away. Then bound antibody is eluted by pH gradient method, and antibody fragments are detected by SDS-PAGE and pooled. The antibody can be concentrated by filtration using a conventional method. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieve, ion exchange. The resulting product requires to be immediately frozen, such as −70° C., or lyophilized.
‘Alleviation of immunosuppression’ means to inhibit or suppress the immune function of one or more cells that normally express CD96 and at least partially eliminate, remove or overcome the normal activity or function of CD96. Typically, one or more cells that normally express CD96 are T cells, including CD4+ and CD8+ T cells, γδ T cells, Natural Killer T (NKT) cells, and NK cells. In some embodiments, alleviation of immunosuppression may include or involve the abolition of peripheral tolerance to foreign pathogens, host cells exhibiting foreign pathogens (e.g., displaying foreign pathogen-derived polypeptides in autologous MHC) and/or the cancer cells or tissues of the host.
The term ‘blocking’ refers to the ability of the antibody or the antigen-binding fragment thereof of the present disclosure to block, partially block, interfere with, decrease, inhibit, reduce or inactivate a target protein, ie, CD96 and/or its ligands (such as CD155). Thus, those skilled in the art understand that the term ‘blocking’ may cover the loss of all and/or part of the activity of the ligand or receptor. The activity of the ligand or receptor can be suppressed or inhibited by a compound that binds to the active site of the ligand/receptor protein, or by other means, such as inactivating a second protein that activates the inhibited first protein. For example, all and/or partial inhibition of the interaction between CD96 and CD155 can be characterized by increased NK cell activation.
The term ‘tumor’ refers to all the growth and proliferation of neoplastic cells, irrespective of malignant or benign, and all pre-cancerous and cancerous cells and tissues.
The terms ‘cancer’ and ‘cancerous’ refer to or describe a physiological disease in mammals that is typically characterized by unregulated cell growth. The terms ‘cancer’, ‘cancerous’, ‘cell proliferative disorder’, ‘proliferative disorder’ and ‘tumor’ are not mutually exclusive when mention in the present invention.
When applied to an animal, human, subject, cell, tissue, organ or biological fluid, ‘give’, ‘administer’ and ‘treat’ refer to the contact of an exogenous drug, therapeutic agent, diagnostic agent or composition to animal, human, subject, cell, tissue, organ or biological fluid. ‘give’, ‘administer’ and ‘treat’ may refer to, for example, treatment, pharmacokinetics, diagnosis, research and experimental methods. Treatment of a cell includes contact of a reagent with a cell, and contact of a reagent with a fluid, wherein the fluid is in contact with the cell. ‘Give’, ‘administer’ and ‘treat’ also mean treating cells in vitro and ex vivo by an agent, diagnosis, binding composition, or by another cell. When applied to a human, veterinary or research subject, ‘treat’ refers to therapeutic treatment, preventive or prophylactic measures, research and diagnostic applications.
‘Therapy’ means the administration to a patient of an internal or external therapeutic agent, such as a composition comprising any one of the antibodies or the antigen-binding fragments thereof, or the nucleic acid molecules encoding the antibodies or the antigen-binding fragments thereof, said patient has one or a variety of disease symptoms, and the therapeutic agents are known to have therapeutic effect on these symptoms. Generally, a therapeutic agent is administered to a patient or population under treatment in an amount that effectively alleviates the symptoms of one or more diseases to induce the deterioration of such symptoms or inhibits the development of such symptoms to any clinically measurable degree. The amount of therapeutic agent (also known as a ‘therapeutically effective amount’) that is effective in alleviating the symptoms of any particular disease can vary depending on numerous factors, such as the patient's disease state, age and weight, and the ability of the drug to give the desired effect in the patient. A clinical test method that a doctor or other health care professional usually uses to assess the severity or progression of the symptoms can be used to determine whether the symptoms of the disease have been alleviated. Although embodiments of the present disclosure (e.g., treatment methods or articles) may not be effective in alleviating each symptom of target disease, they should reduce symptoms of the target disease in a statistically significant number of patients confirmed by any statistical test method known in the art such as Student t-test, Chi-square test, Mann and Whitney's The U test, Kruskal-Wallis test (H test), Jonckheere-Terpstra test and Wilcoxon test.
An ‘effective amount’ includes an amount sufficient to ameliorate or prevent the symptoms or conditions of a medical disease. An effective amount also means an amount sufficient to allow or facilitate diagnosis. An effective amount for a particular patient or veterinary subject can vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side-effects. An effective amount can be the maximum dose or dosage regimen to avoid significant side-effects or toxic effects.
‘Exogenous’ refers to a substance that is produced outside the organism, cell or human as appropriate. ‘Endogenous’ refers to a substance that is produced in a cell, organism or human body as appropriate.
‘Homology’ refers to sequence similarity between two polynucleotide sequences or between two polypeptides. When positions in two compared sequences are occupied by the same bases or amino acid monomer subunits. For example, if each position of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of compared positions ×100. For example, when the sequences are optimally compared, if 10 positions in the two sequences have 6 matches or homology, then the two sequences are 60% homologous; if 100 positions in the two sequences have 95 matches or homology, then the two sequences are 95% homologous. Generally, comparisons are made when the two sequences are compared for the greatest percentage of homology.
As used herein, the expressions ‘cell’, ‘cell line’ and ‘cell culture’ are used interchangeably, and all such names include offspring. Thus, the words ‘transformants’ and ‘transformed cells’ include primary test cells and cultures derived therefrom regardless of the number of passages. It should also be understood that due to intentional or unintentional mutations, all offspring cannot have the exactly same DNA content. The mutant offsprings that have the same functional or biological activity as those originally screened in the transformed cells are included. Where different names are meant, the meaning of which are clearly understood from the context.
As used herein, ‘polymerase chain reaction’ or ‘PCR’ refers to a procedure or technique in which a specific amount of nucleic acid, RNA and/or DNA is amplified as described in, for example, U.S. Pat. No. 4,683,195. Generally, it is necessary to obtain sequence information from the terminal of or outside the target region so that oligonucleotide primers can be designed; these primers are identical or similar in sequence to the corresponding strands of the template to be amplified. The 5′ terminal nucleotides of the two primers may coincide with the terminal of the material to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA and cDNA, phage or plasmid sequences transcribed from total cellular RNA. See generally Mullis et al. (1987) Cold Spring Harbor Symp. Ouant. Biol. 51:263; Edited by Erlich, (1989) PCR TECHNOLOGY (Stockton Press, N.Y.). The PCR used herein is considered as an example, but not the only example, of a nucleic acid polymerase reaction method for amplifying the test nucleic acid sample. The method includes using known nucleic acids as primers and nucleic acid polymerases to amplify or produce specific parts of nucleic acids.
‘Optional’ or ‘optionally’ means that the event or environment described later may, but not necessarily, occur, and the description includes situations where the event or environment occurs or not. For example, ‘optionally comprising 1-3 antibody heavy chain variable regions’ means that an antibody heavy chain variable region of a particular sequence may, but not necessarily, be present.
‘Pharmaceutical composition’ means a mixture containing one or more of the compounds or a physiological/pharmaceutically acceptable salt or prodrug thereof described herein with other chemical components, such as physiological/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and exerts the biological activity.
Furthermore, the present disclosure includes a medicament for treating a disease associated with CD96, comprising a monoclonal antibody or an antibody fragment thereof of the present disclosure as an active ingredient.
There is no limitation on the diseases related to CD96, as long as it is a disease associated with CD96, for example, the therapeutic response induced by the molecules disclosed in the present disclosure can be reduced by binding human CD96 for blocking the binding of CD96 to its ligand CD155, thereby reducing NK inhibition of cells. Therefore, the molecules of the present disclosure are useful for those who suffer a tumor, cancer or infectious disease when in preparations and formulations suitable for therapeutic applications.
Further, the present disclosure relates to a method for immunodetection or measurement of CD96, a reagent for immunodetection or measurement of CD96, a method for immunodetection or measurement of cells expressing CD96, and a diagnostic agent for diagnosing a disease associated with CD96. It contains the monoclonal antibody or the antibody fragment that specifically recognizes and binds to the amino acid sequence of the extracellular region or its three-dimensional structure of human CD96 as an active ingredient.
In the present disclosure, the method for detecting or determining the amount of CD96 may be any known method. For example, it includes immunological detection or measurement method.
The immunodetection or measurement method is a method for detecting or measuring the amount of antibody or antigen using a labeled antigen or antibody. Examples of the immunodetection or measurement method include radioimmunoassay using radioactive substance-labeled immune antibody method (RIA), enzyme immunoassay (EIA or ELISA), fluorescent immunoassay (FIA), luminescent immunoassay, western blotting, physicochemical method, etc.
The above-mentioned diseases associated with CD96 can be diagnosed by detecting or measuring cells expressing CD96 with the monoclonal antibodies or antibody fragments of the present disclosure.
In order to detect cells expressing a polypeptide, a known immunodetection method can be used, preferably an immunoprecipitation method, a fluorescent cell staining method, an immunotissue staining method, or the like. Additionally, a fluorescent antibody staining method using the FMAT8100HTS system (Applied Biosystem) can be used.
In the present disclosure, there is no particular restriction on the living sample for detecting or measuring CD96, as long as it has the possibility of including cells expressing CD96, such as tissue cells, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid or culture fluid.
The diagnostic agent containing the monoclonal antibody or the antibody fragment thereof of the present disclosure may further contain an agent for performing an antigen-antibody reaction or an agent for testing the reaction according to a required diagnostic method. Reagents for performing the antigen-antibody reaction include buffers, salts and the like. The reagent for measurement includes reagents commonly used in immunodetection or measurement methods, such as a labeled second antibody that recognizes the monoclonal antibody, the antibody fragment thereof or conjugate thereof and a substrate corresponding to the label, and the like.
The disclosure is further described below with reference to the embodiments, but these embodiments are not intended to limit the scope of the disclosure. Experimental methods without specifying certain conditions in the embodiments of the present disclosure are generally in accordance with the conventional conditions, such as Using Antibodies: A Laboratory Manual, and Molecular Cloning: A Laboratory Manual, Cold Spring Harbor; or the conditions proposed by the manufacturers of raw materials or commodities. Reagents are commercially available conventional reagents unless otherwised specified.
Human CD96 protein (Uniprot: P40200-2) was used as a template for the CD96 of the present disclosure to design the amino acid sequences of the antigens and proteins for following assays involved in the present disclosure. Optionally, the CD96 proteins fused with different tags were cloned into the pHr vector (self-made) or the pXC-17.4 vector (LONZA) respectively, and transiently expressed in 293 cells or stably expressed in CHO cells, thus purifying the encoded antigen and the protein to be tested of the present disclosure. The following CD96 antigens refer to human CD96 unless otherwise specified.
CD96 extracellular region with Flag tag (SEQ ID NO: 1): CD96-Flag, for immunizing mice
MEKKWKYCAVYYIIQIHFVKGVWEKTVNTEENVYATLGSDVNLTCQTQTV
Note: The underlined part is the signal peptide and the italic part is the Flag-tag.
Fusion protein of CD96 extracellular domain and mIgG2a Fc (SEQ ID NO: 2): CD96-mFc for immunization
MEFGLSWLFLVAILKGVQCVWEKTVNTEENVYATLGSDVNLTCQTQTVGF
VDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDW
MSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV
TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVE
KKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK
Note: The underlined part is the signal peptide and the italic part is the mFc.
Full-length CD96 (SEQ ID NO: 3): for constructing CD96 overexpressing cell lines for immunization and test
MEKKWKYCAVYYIIQIHFVKGVWEKTVNTEENVYATLGSDVNLTCQTQTV
TCIQEPNESDLPYHEMETL
Note: The underlined part is the signal peptide, the normal part is the extracellular region, and the italic part is the transmembrane region and the intracellular region.
CD96 extracellular region with His tag (SEQ ID NO: 4): CD96-His, for following assays
MEKKWKYCAVYYIIQIHFVKGVWEKTVNTEENVYATLGSDVNLTCQTQTV
Note: The underlined part is the signal peptide, the italic part is His-tag.
Fusion protein of CD96 extracellular region and hIgG1Fc (SEQ ID NO: 5): CD96-Fc, for following assays
MEFGLSWLFLVAILKGVQCVWEKTVNTEENVYATLGSDVNLTCQTQTVGF
NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Note: The underlined part is the signal peptide and the italic part is the Fc.
The sample was centrifuged at high speed to remove impurities and concentrated to an appropriate volume. The flag affinity column was equilibrated with 2-5 column volumes of 0.5×PBS. The cell expression supernatant sample from which impurities have been removed was loaded onto the column. The column was washed with 0.5×PBS until the readout at A280 was reduced to baseline. The column was washed with PBS containing 0.3M NaCl to remove the impurity proteins and efflux was collected. The target protein was eluted with 0.1M acetic acid (pH3-4) or Flag peptide solution and the elution peak of the target product was collected, and the pH was adjusted to neutral.
The collected elution was concentrated and may further purified by, for example gel chromatography Superdex 200 (GE) and the mobile phase was PBS, and the peaks of the multimer and heteroprotein were removed and the elution peak of the target product was collected. The obtained protein was identified as correct by electrophoresis, peptide mapping, and LC-MS, and aliquoted for later use.
The samples of cell expression supernatant were centrifuged at high speed to remove impurities, the buffer was replaced with PBS, and imidazole was added to a final concentration of 5 mM. The nickel column was equilibrated with 2-5 column volumes of PBS containing 5 mM imidazole. After the replacement of PBS, the samples of supernatant were loaded onto the column for binding, and the medium may choose nickel columns from different companies. The column was washed with PBS containing 5 mM imidazole until the readout at A280 was reduced to baseline. The column was then washed with PBS+10 mM imidazole to remove non-specifically bound heteroproteins, and the effluent was collected. The target protein was eluted with PBS containing 300 mM imidazole, and the elution peak was collected.
The collected elution was concentrated and may further purified by, for example gel chromatography Superdex 200 (GE) and the mobile phase was PBS, and the peaks of the multimer and heteroprotein were removed, and the elution peak of the target product was collected. The obtained protein was identified as correct by electrophoresis, peptide mapping, and LC-MS, and aliquoted for later use.
Protein G is preferred for purification of mouse hybridoma supernatants for affinity chromatography. The cultured hybridomas were centrifuged to collect the supernatant, and 10-15% by volume of 1M Tris-HCl (pH 8.0-8.5) was added to adjust the pH of supernatant. The Protein G column was washed with 3-5 column volumes of 6 M guanidine hydrochloride, and then 3-5 column volumes of pure water. The column was equilibrated with 3-5 column volumes of a buffer system such as 1×PBS (pH7.4). The cell supernatant was loaded with low flow rate for binding, and the flow rate was controlled to maintain a retention time of about 1 minute or longer. The chromatography column was washed with 3-5 column volumes of 1×PBS (pH7.4) until the UV absorption fell back to baseline. The sample was eluted with 0.1 M acetic acid/sodium acetate (pH 3.0) buffer, the elution peak was collected according to UV detection, and the eluted product was temporarily stored after the pH of which was rapidly adjusted to pH 5-6 using 1 M Tris-HCl (pH8.0). The eluted product can be subjected to solution replacement by methods well known to those skilled in the art, such as ultrafiltration concentration with ultrafiltration tube and solution replacement with a desired buffer system, or molecular exclusion such as G-25 desalting to replace with a desired buffer system, or high-resolution molecular exclusion columns such as Superdex 200 to remove multimer components from the eluted product to improve the purity of sample.
4. Protein A Affinity Chromatography to Extract Fusion Proteins or Antibodies with Fc-Tag
First, the culture supernatant of cells expressing the Fc fusion protein or antibody was centrifuged at high speed to collect the supernatant. ProteinA affinity column was washed with 3-5 column volumes of 6M guanidine hydrochloride, and then 3-5 column volumes of pure water. The column was equilibrated with 3-5 column volumes of a buffer system such as 1×PBS (pH 7.4). The cell supernatant was loaded with a low flow rate for binding, and the flow rate was controlled to maintain a retention time of about 1 minute or longer. After the binding was completed, the chromatography column was washed with 3-5 column volumes of 1×PBS (pH7.4) until the UV absorption fell back to baseline. The sample was eluted with 0.1 M acetic acid/sodium acetate (pH3.0-3.5) buffer, and the eluted peak was collected according to UV detection. The eluted product was temporatily stored after the pH of which was rapidly adjusted to pH 5-6 using 1M Tris-HCl (pH 8.0). The eluted product can be subjected to solution replacement by methods well known to those skilled in the art, such as using ultrafiltration concentration with ultrafiltration tube and solution replacement with a desired buffer system, or molecular exclusion such as G-25 desalting to replace with a desired buffer system, or high-resolution molecular exclusion columns such as Superdex 200 to remove multimer components from the eluted product to improve the purity of sample.
1. Immunization
Mice were immunized to produce the anti-human CD96 monoclonal antibody. SJL white mice, female, 6-8 weeks old (Beijing Vital River Laboratory Animal Technology Co., Ltd., animal permit number: SCXK (Beijing) 2012-0001) were used and raised in a SPF laboratory. The mice were kept in the laboratory for 1 week under 12/12 hours light/dark cycle, at a temperature of 20-25° C., and humidity 40-60%. The mice that became adapted to the environment were immunized according to the following protocol. Immunogens were human CD96 extracellular region (SEQ ID NO: 1 or 2) with Flag-tag or mFc-tag, and CHO cell line overexpressing human CD96.
Immunization protocol A: TiterMax® Gold Adjuvant (Sigma Cat No. T2684) and Thermo Imject® Alum (Thermo Cat No. 77161) adjuvant were used for cross-immunization. The ratio of antigen to adjuvant (TiterMax® Gold Adjuvant) was 1:1, the ratio of antigen to adjuvant (Thermo Imject® Alum) is 3:1, 50 μg/mouse for the primary immunization, and 25 μg/mouse for the booster immunization. The antigen was emulsified and inoculated on day 0, 14, 28, 42, 56. On day 0, each mouse was intraperitoneally (IP) injected with 50 μg emulsified antigens. On day 14, each mouse was subcutaneously (SC) multiply injected (usually 6-8 points on the back) with 25 μg. On day 28 and day 42, the antigen was back or intraperitoneally injected according to the swelling conditions on the back and abdomen. Blood was sampled on day 21, 35, 49 and 63, and antibody titer in mouse serum were determined by ELISA. After 4-5 times of immunization, mice with high antibody titer in the serum and with the titer tending to be stationary were selected for splenocyte fusion Immunization was boosted 3 days before splenocyte fusion, and each mouse was IP injected with antigen solution prepared with physiological saline.
Immunization protocol B: Mice were immunized with Quick Antibody-Mouse 5W (KX0210041) adjuvant. The ratio of antigen to adjuvant was 1:1, 25 μg/mouse for both primary immunization and booster immunization. The antigen and adjuvant were quickly and thoroughly mixed, and then inoculated on day 0, 21 and 35. On day 0, the hind leg of each mouse was intramuscularly (IM) injected with 25 μg antigen. On the day 21 and 35, each mouse was injected with 25 μg in the same manner (depending on the titer, whether or not the third immunization was performed). Blood was sampled on day 28 and 42 and the antibody titer in mouse serum was determined by ELISA. Mice with high antibody titers in the serum and with the titer tending to be stationary were selected for splenocyte fusion Immunization was boosted 3 days before splenocyte fusion, and each mouse was IP injected with antigen solution prepared with physiological saline.
2. Spleen Cell Fusion
The spleen lymphocytes and myeloma cells Sp2/0 (ATCC® CRL8287™) were fused to obtain hybridoma cells by optimized PEG-mediated fusion procedure. The fused hybridoma cells were re-suspended in complete medium (DMEM medium containing 20% FBS, 1×HAT, 1×OPI) at a density of 0.5-1×10{circumflex over ( )}6/ml, then aliquoted into a 96-well cell culture plate (1×105/150 μl/well). After incubation at 37° C. and 5% CO2 for 3-4 days, 100 μl/well of HAT complete medium was supplemented. The cell culturing was continued for 3-4 days until needle-like clones were formed. After removing supernatant, 200 μl/well of HT complete medium (RPMI-1640 medium containing 20% FBS, 1×HT and 1×OPI) was added, incubating at 37° C., 5% CO2 for 3 days, and then an ELISA test was performed.
3. Screening of Hybridoma Cells
Based on the hybridoma cell growth density, ELISA tests for the hybridoma culture supernatant were performed. Cell-binding experiments and cell-blocking experiments were performed with supernatant of positive cells tested by ELISA. The wells that were positive for both binding and blocking were expanded in time for cryopreservation and subcloning was performed two to three times until a single cell clone was obtained.
CD96-binding ELISA, cell-binding assay and cell-blocking assay were also performed for each subcloned cell. Hybridoma clones were screened through the above experiments, and antibodies were further prepared by serum-free cell culture. The antibodies were purified according to the purification embodiments (item 3 of Embodiment 2) for use in the test examples.
4. Sequencing of Positive Hybridoma Clones
The process of cloning sequences from positive hybridomas is as follows:
The logarithmic growth phase hybridoma cells were collected, RNA was extracted using Trizol (Invitrogen, Cat No. 15596-018) according to instructions of the Kit, and reverse transcription was performed using PrimeScript™ Reverse Transcriptase Kit (Takara, Cat No. 2680A). The reverse-transcribed cDNA was amplified by PCR using a mouse Ig-Primer Kit (Novagen, TB326 Rev. B 0503) and sent to a sequencing company for sequencing. The amino acid sequences of the heavy and light chain variable region DNA sequences corresponding to the murine antibodies m1718, m1719, m1720, m1721 and m1722 were obtained (the amino acid residues of the CDRs in VH/VL are numbered and annotated according to the Kabat numbering system, and the underlined sequence is CDR):
INPSYGITDYNQNFKDKATLTVDQSSSTAYMQLNSLTSEDSAVYYCAIQL
RLPGYFDVWGTGTTVIVSS
ANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLKYDEFPYTFGG
IWGDGNTNYHSVLISRLSIRKDDSKSQVFLKLNSLQTDDTATYYCAKNNY
YGSRYGYPMDYWGQGTSVTVSS
ASTRHTGVPERFTGSGSGTDFTLTIDNVQSEDLADYFCQQYGSSVLTFGA
INPSYGISSYNQKFKGKATLTVDQSSSTAYMHLNSLTSEDSAVYYCARQL
RLPGYFDVWGTGTTVTVSS
ASRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLKYDEFPYTFGG
IWGDGSTNYHSALISRLSISKDDSKSQVFLNLNSLQTDDTATYYCAKNYF
YGSRYGYAMDSWGQGISVTVSS
AKTLIETVASRFSGSGSGTQYSLKINSLQPEDFGSFYCQHHYGTPYTFGG
LHPNSGTTSFNEKFKIKTTLTIDKSSSTAYMQLSSLTSEDSAIYYCASDY
SGPFAYWGQGTLVTVSA
SKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWRSNPLTFGAG
The CDR sequences in the light chains and heavy chains of each antibody are shown in Table 1.
The light chain and heavy chain variable regions of the murine antibody were linked to the light chain constant region (SEQ ID NO: 117) and the heavy chain constant region (SEQ ID NO: 118) of the human antibody, respectively, to form a chimeric antibody. The chimeric antibody corresponding to m1718 antibody was named ch1718, and other antibodies were named by analogy.
By aligning germline gene database of IMGT human antibody heavy chain and light chain variable region and MOE software, the heavy chain and light chain variable region germline genes with high homology with murine antibodies were respectively selected as templates. The CDRs of murine antibodies were respectively grafted into the corresponding human templates to form variable region sequences with the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. According to the experimental requirements, the key amino acids in the backbone sequence were back-mutated into the amino acid corresponding to the murine antibody to ensure the original affinity, and the humanized anti-CD96 monoclonal antibody was obtained. The amino acid residues were identified and annotated according to the natural numbers when performing back mutations.
4.1 Humanization of Hybridoma Clone m1718
(1) Selection of Humanized Framework for m1718
For mouse antibody m1718, the template of humanized light chain is IGKV1-16*01 and hjk4.1, and the template of humanized heavy chain is IGHV1-3*01 and hjh6.1. After CDR grafting, humanized antibody h1718-001 was obtained and its sequences of humanized variable region are as follows:
EVQLVQSGAEVKKPGASVKVSCKASGYTFT
DYNMN
WVRQAPGQRLEWMG
V
INPSYGITDYNQNFKD
RVTITRDTSASTAYMELSSLRSEDTAVYYCAR
QL
RLPGYFDV
WGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITC
KASQDINNYLN
WFQQKPGKAPKSLIY
R
ANRLVD
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
LKYDEFPYTF
GG
GTKVEIK
Note: The order of various regions is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the italic part is FR sequence, and underlined part is CDR sequence.
(2) The design of h1718 series back mutations are as follows:
(3) The combinations of variable region sequences of h1718 series humanized antibodies are as follows:
(4) The specific sequences of the variable regions of h1718 series humanized antibodies are as follows:
DIQMTQSPSSLSASVGDRVTITCKASQDINNYLIVWFQQKPGKAPKSLIY
RANRLVDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLKYDEFPYTFG
GGTKVEIK
DIQMTQSPSSLSASVGDRVTITCKASQDINNYLIVWFQQKPGKAPKTLIY
RANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLKYDEFPYTFG
GGTKVEIK
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMNWVRQAPGQRLEWMGV
INPSYGITDYNQNFKDRVTITRDTSASTAYMELSSLRSEDTAVYYCARQL
RLPGYFDVWGQGTTVTVSS
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMNWVRQAPGQRLEWIGV
INPSYGITDYNQNFKDRVTITVDTSASTAYMELSSLRSEDTAVYYCARQL
RLPGYFDVWGQGTTVTVSS
EVQLVQSGAEVKKPGASVKVSCKASGYTITDYNMNWVRQAPGQRLEWIGV
INPSYGITDYNQNFKDRVTITVDTSASTAYMELSSLRSEDTAVYYCAIQL
RLPGYFDVWGQGTTVTVSS
EVQLVQSGAEVKKPGASVKVSCKASGYTITDYNMNWVKQAPGQRLEWIGV
INPSYGITDYNQNFKDKVTITVDTSASTAYMELSSLRSEDTAVYYCAIQL
RLPGYFDVWGQGTTVTVSS
(5) Hotspot mutation of h1718-VL:
The NN in CDR1 of h1718 series humanized VL (ie, SEQ ID NO: 19, KASQDINNYLN) was mutated to NQ, NT, NL to improve the stability of the antibodies. The general formula of h1718 VL CDR1 sequence is KASQDINX1YLN (SEQ ID NO: 52), wherein X1 is selected from: N, T, L and Q. Specific h1718VL CDR1 mutants include KASQDINQYLN (SEQ ID NO: 108), KASQDINTYLN (SEQ ID NO: 109) and KASQDINLYLN (SEQ ID NO: 110).
h1718-VL1 can be mutated to the following light chain variable region sequences:
The combinations of the variable region sequences of h1718 series humanized antibodies are as follows:
4.2 Humanization of Hybridoma Clone m1719
(1) Selection of Humanized Framework for m1719
For murine antibody m1719, the template of humanized light chain is IGKV1-12*01 and hjk4.1, and the template of humanized heavy chain is IGHV2-26*01 and hjh6.1. After CDR crafting, humanized antibody h1719-001 was obtained and its sequences of humanized variable region are as follows:
EVTLKESGPVLVKPTETLTLTCTVSGFSLS
SYGVS
WIRQPPGKALEWLA
V
IWGDGNTNYHSVLIS
RLTISKDTSKSQVVLTMTNMDPVDTATYYCAR
NNY
YGSRYGYPMDY
WGQGTTVTVSS
DIQMTQSPSSVSASVGDRVTITC
KATQDVGTAVA
WYQQKPGKAPKLLIY
W
ASTRHT
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGSSVLTFGG
GTKVEIK
Note: The order of various regions is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the italic part is FR sequence, and underlined part is CDR sequence.
(2) The design of h1719-001 back mutations are as follows:
(3) The combinations of variable region sequences of h1719 series humanized antibodies are as follows:
(4) The specific sequences of the variable regions of h1719 series humanized antibodies are as follows:
DIQMTQSPSSVSASVGDRVTITCKATQDVGTAVAWYQQKPGKAPKLLIYW
ASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGSSVLTFGG
GTKVEIK
DIQMTQSPSSVSASVGDRVTITCKATQDVGTAVAWYQQKPGKSPKWYWAS
TRHTGVPERFSGSGSGTDFTLTISSLQPEDFATYFCQQYGSSVLTFGGGT
KVEIK
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVSWIRQPPGKALEWLAV
IWGDGNTNYHSVLISRLTISKDTSKSQVVLTMTNMDPVDTATYYCARNNY
YGSRYGYPMDYWGQGTTVTVSS
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVSWVRQPPGKALEWLAV
IWGDGNTNYHSVLISRLTISKDTSKSQVVLTMTNMDPVDTATYYCAKNNY
YGSRYGYPMDYWGQGTTVTVSS
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVSWVRQPPGKGLEWLGV
IWGDGNTNYHSVLISRLTISKDTSKSQVVLTLTNMDPVDTATYYCAKNNY
YGSRYGYPMDYWGQGTTVTVSS
(5) Hotspot Mutation of h1719-VH:
The NN in CDR3 of h1719 VH (ie, SEQ ID NO: 19, KASQDINNYLN) was mutated to QN, NY, NQ, and M was mutated to L or I to improve the stability of the antibodies. The general formula of h1719VH CDR3 sequence is X2X3YYGSRYGYPX4DY (SEQ ID NO: 64), wherein X2 is selected from: N and Q, X3 is selected from: N, Y and Q, X4 is selected from: M, L and I. Specific h1719 VH CDR3 mutants may include, but are not limited to QNYYGSRYGYPLDY (SEQ ID NO: 111), NYYYGSRYGYPLDY (SEQ ID NO: 112), NQYYGSRYGYPLDY (SEQ ID NO: 113), QNYYGSRYGYPIDY (SEQ ID NO: 114), NYYYGSRYGYPIDY (SEQ ID NO: 115), NQYYGSRYGYPIDY (SEQ ID NO: 116).
h1719-VH3 can be mutated to the following heavy chain variable region sequences:
The combinations of variable region sequences of h1719 series humanized antibodies are as follows:
4.3 Humanization of Hybridoma Clone m1721
(1) Selection of Humanized Framework for m1721
For mouse antibody m1721, the template of humanized light chain is IGKV1-39*01 and hjk4.1, and the template of humanized heavy chain is IGHV2-26*01 and hjh6.1. After CDR crafting, humanized antibody h1721-001 was obtained and its sequences of humanized variable region are as follows:
EVTLKESGPVLVKPTETLTLTCTVSGFSLS
SYGVN
WIRQPPGKALEWLA
V
IWGDGSTNYHSALIS
RLTISKDTSKSQVVLTMTNMDPVDTATYYCAR
NYF
YGSRYGYAMDS
WGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITC
RASENIYSSLA
WYQQKPGKAPKWY
NAK
TLIE
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QHHYGTPYTF
GGGT
KVEIK
Note: The order of various regions is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the italic part is FR sequence, and underlined part is CDR sequence.
(2) The design of h1721-001 back mutations are as follows:
(3) The combinations of variable region sequences of h1721 series humanized antibodies are as follows:
(4) The specific sequences of the variable regions of h1721 series humanized antibodies are as follows:
DIQMTQSPSSLSASVGDRVTITCRASENIYSSLAWYQQKPGKAPKLLIYN
AKTLIEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPYTFGG
DIQMTQSPSSLSASVGDRVTITCRASENIYSSLAWYQQKPGKAPKLLVYN
AKTLIEGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHHYGTPYTFGG
GTKVEIK
DIQMTQSPSSLSASVGDRVTITCRASENIYSSLAWYQQKPGKSPKLLVYN
AKTLIEGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHHYGTPYTFGG
GTKVEIK
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVNWIRQPPGKALEWLAV
IWGDGSTNYHSALISRLTISKDTSKSQVVLTMTNMDPVDTATYYCARNYF
YGSRYGYAMDSWGQGTTVTVSS
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVNWIRQPPGKALEWLGV
IWGDGSTNYHSALISRLTISKDTSKSQVVLTMTNMDPVDTATYYCAKNYF
YGSRYGYAMDSWGQGTTVTVSS
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVNWIRQPPGKALEWLGV
IWGDGSTNYHSALISRLTISKDTSKSQVVLTLTNMDPVDTATYYCAKNYF
YGSRYGYAMDSWGQGTTVTVSS
EVTLKESGPVLVKPTETLTLTCTVSGFSLSSYGVNWVRQPPGKGLEWLGV
IWGDGSTNYHSALISRLTISKDTSKSQVVLTLTNMDPVDTATYYCAKNYF
YGSRYGYAMDSWGQGTTVTVSS
4.4 Humanization of Hybridoma Clone m1722
(1) Selection of Humanized Framework for m1722
For murine antibody m1722, the template of humanized light chain is IGKV1-39*01 and hjk2.1, and the template of humanized heavy chain is IGHV1-69*02 and hjh4.1. After CDR crafting, humanized antibody h1722-001 was obtained and its sequences of humanized variable region are as follows:
EVQLVQSGAEVKKPGSSVKVSCKASGGTFS
DYWMH
WVRQAPGQGLEWMG
M
LHPNSGTTSFNEKFKI
RVTITADKSTSTAYMELSSLRSEDTAVYYCAR
DY
SGPFA
YWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITC
SASSSVNYIH
WYQQKPGKAPKWY
DTSK
LAS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQWRSNPLT
FGQGTK
LEIK
Note: The order of various regions is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the italic part is FR sequence, and underlined part is CDR sequence.
(2) The design of h1722-001 back mutations are as follows:
(3) The combinations of variable region sequences of h1722 series humanized antibodies are as follows:
(4) The specific sequences of the variable regions of h1722 series humanized antibodies are as follows:
DIQMTQSPSSLSASVGDRVTITCSASSSVNYIHWYQQKPGKAPKLLIYDT
SKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWRSNPLTFGQG
TKLEIK
DIQMTQSPSSLSASVGDRVTITCSASSSVNYIHWYQQKPGKAPKRWIYDT
SKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWRSNPLTFGQG
TKLEIK
DIQLTQSPSSLSASVGDRVTITCSASSSVNYIHWYQQKPGKAPKRWIFDT
SKLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQWRSNPLTFGQG
TKLEIK
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYWMHWVRQAPGQGLEWMGM
LHPNSGTTSFNEKFKIRVTITADKSTSTAYMELSSLRSEDTAVYYCARDY
SGPFAYWGQGTLVTVSS
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYWMHWVRQAPGQGLEWIGM
LHPNSGTTSFNEKFKIRVTITADKSTSTAYMELSSLRSEDTAVYYCASDY
SGPFAYWGQGTLVTVSS
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYWMHWVKQAPGQGLEWIGM
LHPNSGTTSFNEKFKIRVTITIDKSTSTAYMELSSLRSEDTAVYYCASDY
SGPFAYWGQGTLVTVSS
EVQLVQSGAEVKKPGSSVKVSCKASGNTFSDYWMHWVKQAPGQGLEWIGM
LHPNSGTTSFNEKFKIRTTITIDKSTSTAYMELSSLRSEDTAVYYCASDY
SGPFAYWGQGTLVTVSS
(5) Hotspot Mutation of h1722-VH:
Because there is an acetylated high-risk site NS, we mutated NS to KS or QS to improve the chemical stability of the antibody. The general formula of h1722-VH CDR2 sequence is MLHPX5SGTTSFNEKFKI (SEQ ID NO: 119), wherein X5 is selected from: N, K and Q. Specific h1722 VH CDR2 mutants may include, but are not limited to MLHPKSGTTSFNEKFKI (SEQ ID NO: 120) or MLHPQSGTTSFNEKFKI (SEQ ID NO: 121).
h1722-VH2 can be mutated to the following heavy chain variable region sequences:
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYWMHWVRQAPGQGLEWIGM
LHPKSGTTSFNEKFKIRVTITADKSTSTAYMELSSLRSEDTAVYYCASDY
SGPFAYWGQGTLVTVSS
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYWMHWVRQAPGQGLEWIGM
LHPQSGTTSFNEKFKIRVTITADKSTSTAYMELSSLRSEDTAVYYCASDY
SGPFAYWGQGTLVTVSS
The combinations of variable region sequences of h1722 series humanized antibodies are as follows:
The heavy chain variable regions described above can be recombinantly expressed with the heavy chain constant region sequence such as SEQ ID NO: 117 to obtain the final complete heavy chain sequence. The light chain variable regions described above can be recombinantly expressed with the light chain constant region sequence such as SEQ ID NO: 118 to obtain the final complete light chain sequence.
Light Chain Constant Region:
Using conventional technical methods in the art, the light chain variable regions and heavy chain variable regions described above can be recombinantly expressed with other optional humanized constant regions and functionally modified humanized constant regions.
Monkey CD96 antigen for following assays: Monkey CD96-3×Flag (SEQ ID NO: 95)
MEFGLSWLFLVAILKGVQCVWGKPFNTEENIYATLGSDVNLTCQTQAKGF
The underlined part is the signal peptide and the italic part is 3×Flag-tag. For the preparation method, see item 1 of Embodiment 2.
The performance and beneficial effects of the present disclosure were verified by following biochemical test methods:
The binding capacity of the anti-CD96 antibody was tested by ELISA to determine the binding of the antibody to human CD96 protein. The His-tagged CD96 fusion protein was used to coat the microtiter plate, and the intensity of the signal after adding with the antibody was used for evaluating the binding activity of the antibody and CD96. The specific experimental method is as follows:
CD96-His with the sequence of SEQ ID NO: 4 prepared in Embodiment 1 was diluted to a concentration of 2 μg/ml with PBS buffer (Shanghai Yuanpei Biotechnology Co., Ltd. Cat No. B320), pH 7.4, added to a 96-well microtiter plate (Corning, Cat No. CLS3590-100EA) at a volume of 50 μl/well, and placed in an incubator at 37° C. for 2 hours. After discarding the liquid, 250 μl/well of 5% skim milk (BD, Cat No. 232100) blocking solution diluted with PBS was added, and the plate was incubated at 37° C. for 2.5 hours or at 4° C. overnight (16-18 hours) for blocking. After blocking, the blocking solution was discarded, and the plate was washed 4 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20). 50 μl/well of different concentrations of the antibodies to be tested (hybridoma purification antibody or humanized antibody) diluted with sample dilution was added, and the plate was incubated in an incubator at 37° C. for 1 hour. After incubation, the plate was washed for 4 times with PBST, and 50 μl/well of HRP-labeled goat anti-mouse secondary antibody (Jackson Immuno Research, Cat No. 115-035-003) or goat anti-human secondary antibody (Jackson Immuno Research, Cat No. 109-035-003) diluted with sample dilution was added, followed by incubating at 37° C. for 1 hour. After washing the plate 4 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added, and the plate was incubated at room temperature for 5-15 minutes, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a NOVOStar microplate reader, and the EC50 value of the binding of CD96 antibody to human CD96 was calculated (see Table 13).
The results showed that anti-CD96 chimeric antibodies and humanized antibodies are able to specifically bind to human CD96.
The cross-reactive binding capacity of the anti-CD96 antibody to monkey CD96 was tested by ELISA to determine the binding of the antibody to cynomolgus CD96 protein. The 3×FLAG-tagged CD96 fusion protein was used to coat the microtiter plate, and the intensity of the signal after adding with the antibody was used for evaluating the binding activity of the antibody and cynomolgus CD96. The specific experimental method is as follows:
cyno-CD96-3×FLAG with the amino acid sequence of SEQ ID NO: 95 prepared in Embodiment 4 was diluted to a concentration of 2 μg/ml with PBS buffer (Shanghai Yuanpei Biotechnology Co., Ltd. Cat No. B320), pH 7.4, added to a 96-well microtiter plate (Corning, Cat No. CLS3590-100EA) at a volume of 50 μl/well, and placed in an incubator at 37° C. for 2 hours. After discarding the liquid, 250 μl/well of 5% skim milk (BD, 232100) blocking solution diluted with PBS was added, and the plate was incubated in an incubator at 37° C. for 2.5 hours or at 4° C. overnight (16-18 hours) for blocking. After blocking, the blocking solution was discarded, and the plate was washed 4 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20). 50 μl/well of different concentrations of the antibodies to be tested (hybridoma purification antibody or humanized antibody) diluted with sample dilution was added, and the plate was incubated in an incubator at 37° C. for 1 hour. After incubation, the plate was washed for 4 times with PBST, and 50 μl/well of HRP-labeled goat anti-mouse secondary antibody (Jackson Immuno Research, Cat No. 115-035-003) or goat anti-human secondary antibody (Jackson Immuno Research, Cat No. 109-035-003) diluted with sample dilution was added, followed by incubating the plate at 37° C. for 1 hour. After washing the plate 4 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added, and the plate was incubated at room temperature for 5-15 minutes, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a NOVOStar microplate reader, and the EC50 value of the binding of CD96 antibody to monkey CD96 was calculated (see Table 14).
The results showed that CD96 chimeric antibodies and humanized antibodies are able to cross-react with monkey CD96.
The binding capacity of the anti-CD96 antibody was tested by binding experiments of the antibody to human CD96 protein overexpressing CHO-S cells. The full-length CD96 plasmid was transfected into CHO-S cells by electrotransfection, and cells were then screened for two weeks under pressure for the detection of the expression of CD96. After the over-expressing cells were fixed at the bottom of the 96-well plate, the density of the signal after adding the antibody was used to judge the binding activity of the antibody to CD96 overexpressing CHO-S cells. The specific experimental method is as follows:
The cells were seeded at a density of 9×104/100 μL/well in a 96-well plate and cultured overnight. After aspirating the supernatant, the plate was washed once with PBS, subsequently, 100 μl/well immunostaining fixation solution (Biyuntian, P0098) was added and fixed for one hour at room temperature, and the plate was washed three times with PBS. Once the liquid was discarded, 250 μl/well of 5% skim milk (BD, 232100) blocking solution diluted with PBS was added, and the plate was blocked in an incubator at 37° C. for 2.5 hours. After blocking, the blocking solution was discarded, the plate was washed 4 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20), followed by diluting 50 μl/well of different concentrations of the antibodies (hybridoma purification antibody or humanized antibody) to be tested the plate was incubated in an incubator at 37° C. for 2 hours. After incubation, the plate was wash 4 times with PBST. Then 50 μl/well of HRP-labeled goat anti-mouse secondary antibody (Jackson Immuno Research, Cat No. 115-035-003) or goat anti-human secondary antibody (Jackson Immuno Research, Cat No. 109-035-003) diluted with sample dilution was added, thus incubating at 37° C. for 1 hour. After washing the plate 4 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added, the plate was incubated at room temperature for 10-25 min, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a NOVOStar microplate reader, and the EC50 value of the CD96 antibodies to CD96 overexpressing CHO-S cells was calculated (see
The results showed that CD96 chimeric antibodies and humanized antibodies are able to specifically bind to CD96 overexpressing CHO-S cells.
CD155-CHO cells (constructed by Shanghai Hengrui) were seeded in 96-well culture plates at a density of 9×104/100 μL/well and cultured overnight. After aspirating the supernatant, the plate was washed once with PBS, 100 μl/well of immunostaining fixation solution (Biyuntian, Cat No. P0098) was added and fixed for one hour at room temperature, and the plate was washed three times with PBS. After discarding the liquid, 250 μl/well of 5% skim milk (BD, Cat No. 232100) blocking solution diluted with PBS was added, and the plate was blocked in an incubator at 37° C. for 2.5 hours. After blocking, the blocking solution was discarded, subsequently, the plate was washed 4 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20). 50 μl/well of antigen-antibody pre-incubation solution (gradient concentrations of the hybridoma antibody to be tested and CD96-Fc at a final concentration of 0.5 μg/mL were premixed at 37° C. for 30 minutes, or gradient concentrations of humanized antibody samples and Bio-CD96-His at a final concentration of 0.5 μg/mL were premixed at 37° C. for 30 minutes) (Biotin-labeled kit, Dongren Chemical, Cat No. LK03) was added, and the plate was incubated in an incubator at 37° C. for 2 hours. After incubation, the reaction solution in the microtiter plate was discarded, the plate was washed 4 times with PBST, and 50 μl/well of HRP-labeled goat anti-human secondary antibody (Jackson Immuno Research, Cat No. 109-035-003) diluted with sample dilution or HRP-labeled streptavidin diluted with sample dilution (Sigma, Cat No. 52438) was added, followed by incubating at 37° C. for 1 hour. After washing the plate 4 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added, the plate was incubated at room temperature for 10-20 minutes, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a NOVOStar microplate reader, and the EC50 value of the effect of CD96 antibody on blocking the binding between the antigens and CD155-CHO cells was calculated (see
The results showed that CD96 chimeric antibodies and humanized antibodies are able to block the binding of CD96 and CD155-CHO cells.
Protein A biosensor chip was used to capture antibodies to be tested, then CD96 antigen was flowed on the surface of the chip, and real time reaction signal was detected by Biacore to obtain the binding and dissociation curve. After the dissociation of each experimental cycle was completed, the biosensor chip was washed and regenerated with a glycine-hydrochloric acid regeneration solution (pH 1.5).
CMS biosensor chip conjugated with anti-murine Fc antibodies was used to capture antibodies to be tested, then CD96 antigen was flowed on the surface of the chip, and real time reaction signal was detected by Biacore to obtain the binding and dissociation curve. After the dissociation of each experimental cycle was completed, the biosensor chip was washed and regenerated with a regeneration solution of mouse antibody capture kit.
The mobile phases were all CD96-ECD-His.
All anti-CD96 chimeric antibodies ch1718, ch1720, ch1721, ch1719, ch1722 have strong affinity with human CD96, as do exemplary humanized antibodies.
Competitive assays of different antibodies binding to CD96 protein were used to classify binding epitopes of the antibodies. The specific experimental methods are as follows:
Antibody A was diluted to a concentration of 2 μg/ml with PBS buffer (Shanghai Yuanpei Biotechnology Co., Ltd. Cat No. B320), pH 7.4, added to a 96-well microtiter plate (Corning, Cat No. CLS3590-100EA) at a volume of 50 μl/well, and coated at 4° C. overnight. After discarding the liquid, 250 μl/well of 5% skim milk (BD skim milk, Cat No. 232100) blocking solution diluted with PBS was added, and the plate was incubated at 37° C. for 3 hours. After blocking, the blocking solution was discarded, and the plate was washed 5 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20) and stored for later use. Antibody B was diluted to 40 μg/ml and 8 μg/ml with 1% BSA, and Biotinylated CD96 antigen was simultaneously diluted to 4 μg/mL. Subsequently, antibody B and antigen were mixed in a 1:1 volume ratio, pre-incubated at 37° C. for 45 minutes, added into the enzyme plate coated with antibody A, thus incubating the plate in an incubator at 37° C. for 1.5 hours. After incubation, the plate was washed for 5 times with PBST, and 50 μl/well of HRP-labeled streptavidin (Sigma, Cat No. 52438) diluted with sample dilution was added, followed by incubating the plate at 37° C. for 1 hour. After washing the plate 5 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added for color development, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a NOVOStar microplate reader, and the OD value was used to determine whether A and B CD96 antibodies compete with each other. Antibodies that compete with each other fall into the same class of antibodies, otherwise belong to different classes of antibodies (see
The results of competitive assay showed that there was a competition between h1721-003, h1719-014, h1718-012 and ch1720 antibodies, all of which did not compete with h1722-010 antibody.
The epitopes recognized by anti-CD96 antibody were detected by the assay of binding the antibody to different polypeptide fragments of CD96 protein. The fragments of different polypeptides of the CD96 antigen were coated on the microtiter plate. The signal density after the antibody was added was used to judge the binding activity of the antibody and the polypeptide. The specific experimental method is as follows:
The polypeptides were diluted to a concentration of 20 μg/ml with PBS buffer (Shanghai Yuanpei Biotechnology Co., Ltd. Cat No. B320), pH 7.4, added to a 96-well microtiter plate (Corning, Cat No. CLS3590-100EA) at a volume of 50 μl/well, and coated at 4° C. overnight. After discarding the liquid, 250 μl/well of 5% skim milk (BD skim milk, Cat No. 232100) blocking solution diluted with PBS was added, and the plate was incubated in an incubator at 37° C. for 3 hours. After blocking, the blocking solution was discarded, and the plate was washed 5 times with PBST buffer (pH 7.4 PBS containing 0.05% tween-20). 50 μl/well of different concentrations of the antibodies to be tested (hybridoma purification antibody or humanized antibody) diluted with sample dilution was added, and the plate was incubated in an incubator at 37° C. for 2 hours. After incubation, the plate was washed for 5 times with PBST, and 50 μl/well of HRP-labeled goat anti-mouse secondary antibody (Jackson Immuno Research, Cat No. 115-035-003) or goat anti-human secondary antibody (Jackson Immuno Research, Cat No. 109-035-003) or anti-Rat-IgG HRP (Jackson Immuno Research, Cat No. 112-035-003) diluted with sample dilution was added, followed by incubating the plate at 37° C. for 1 hour. After washing the plate 5 times with PBST, 50 μl/well of TMB chromogenic substrate (KPL, Cat No. 52-00-03) was added, the plate was incubated at room temperature for 5-15 min, followed by adding 50 μl/well of 1M H2SO4 to stop the reaction. The absorption value was read at 450 nm with a microplate reader (Thermo Scientific MuLtiskan MK3), and the epitopes that CD96 antibody can recognize were analyzed.
According to the above results, antibodies ch1718, ch1720, ch1721 and ch1719 bind strongly to the #3 antigen fragment (SEQ ID NO: 87). The #3 antigen fragment contains epitopes of antibodies ch1718, ch1720, ch1721 and ch1719.
In order to verify that the binding of the antibody to CD96 protein polypeptide fragment is specific, we designed the following FACS for verification. While polypeptide fragments were incubated and bound to an antibody, epitopes of the antibody binding to CD96 protein were occupied, and then the signal of the antibody binding to CD96 protein on the cell surface decreased. The specific experimental methods are as follows:
The antibody samples were diluted to 1.2 μg/mL with 1% BSA, and the peptides were diluted to 40 μg/mL synchronously. The peptides and antibody sample were mixed at a volume ratio of 1:1 and pre-incubated at 37° C. for 90 minutes. CD96-CHOs cells were collected and washed once in PBS, then dispensed according to 0.5×106/test. The cells with 100 μL of peptide-antibody mixture were resuspended, incubated at 4° C. for 1 hour, followed by washing 3 times with 1% BSA. Cells were resuspended with 100 μL dilution (1:400, 1:40, 1:100) of Alexa Fluor 488 anti-human IgG Fc (thermofisher, A-11013), PE goat anti-mouse IgG (Biolegend, Cat No. 405307), or PE goat anti-Rat IgG (Biolegend, Cat No. 405406), incubated at 4° C. for 40 minutes, followed by washing 3 times with 1% BSA. The cells were resuspended with 200 μL of 1% BSA, MFI of each sample was read on a flow cytometer BD FACSCanto II, and the data were analyzed with GraphPad Prism 5 to make a histogram. MFI difference between the sample without polypeptides incubation and the one incubated with polypeptides was used to determine the antigenic epitope recognized by the CD96 antibody. The test results are shown in
The test results showed that the chimeric antibodies ch1721, ch1719 and ch1718 can bind the epitope segment of SEQ ID NO: 87 in the extracellular region of human CD96.
In order to study the effect of CD96 antibody on the killing capability of NK cells, human peripheral blood mononuclear cells (PBMC) were collected and purified to extracted NK cells. After 4 hours of co-cultured with human colorectal cancer cell line WiDr (Cat No. ATCC-CCL-218), the secretion level of lactate dehydrogenase (LDH) was detected.
The experiment process is briefly described as follows:
The human colorectal cancer cell line WiDr was cultured in MEM medium supplemented with 10% (v/v) fetal bovine serum (FBS) at 37° C. and 5% CO2. Fresh blood was used to obtain PBMC by Ficoll-Hypaque density gradient centrifugation (Stem Cell Technologies). Human primary NK cells were extracted from freshly isolated PBMC (Miltenyi, Cat No. 130-092-657) and cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS and cultured at 37° C. and 5% CO2. Human primary NK cells were seeded into a 6-well cell culture plate with a cell density of about 2×106/ml. After adding 100 U/mL human IL-2 (Peprotech, Cat No. 200-02-100) and culturing overnight, phenol red-free RPMI 1640 medium was used to wash the cells, the cells were resuspended and seeded into a 96-well U-bottom plate with a cell density of about 3×105/well. Synchronously, gradient diluted antibody samples (diluted with PBS) or the equivalent amount of isotype IgG were used as blank control. Wells added with IL-2, NK cells and cancer cells were used as blank controls. After incubating at 37° C. for 1 hour in an incubator at 5% CO2, the target cells WiDr were co-cultured with human primary NK cells at a ratio of 1:1. After incubating at 37° C. for 4 hours in an incubator in 5% CO2, the cell culture supernatant was collected. CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Cat No. G1780) was used to detect the LDH secretion level in the cell culture supernatant. For specific operations, please refer to the reagent instructions. The percentage of specific cell lysis is determined by the following formula:
% lysis=100×(ER−SR1−SR2)/(MR−SR1),
wherein ER, SR (1&2) and MR represent experiments, spontaneous (1 indicates the target cell, 2 indicates human primary NK cells) and maximum LDH release. Spontaneous release is LDH released by target cells or human primary NK cells cultured in the culture medium alone, and the maximum release is LDH measured when all target cells are lysed using lysate.
The experimental results are shown in
Although the specific embodiments of the present invention have been described above, those skilled in the art will understand that these are merely illustrative. Many changes or modifications may be made to these embodiments without departing from the principle and essence of the invention. Therefore, the scope of the invention is defined by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201711107331.5 | Nov 2017 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2018/114797 | 11/9/2018 | WO | 00 |
